NASDAQ:GERN Geron (GERN) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free GERN Stock Alerts $3.30 -0.01 (-0.30%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$3.27▼$3.3450-Day Range$1.75▼$3.4452-Week Range$1.64▼$3.73Volume6.21 million shsAverage Volume20.37 million shsMarket Capitalization$1.80 billionP/E RatioN/ADividend YieldN/APrice Target$5.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Geron alerts: Email Address Geron MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside61.6% Upside$5.33 Price TargetShort InterestBearish9.33% of Shares Sold ShortDividend StrengthN/ASustainability-3.23Upright™ Environmental ScoreNews Sentiment0.38Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.34) to ($0.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.33 out of 5 starsMedical Sector351st out of 939 stocksPharmaceutical Preparations Industry166th out of 441 stocks 3.5 Analyst's Opinion Consensus RatingGeron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.33, Geron has a forecasted upside of 61.6% from its current price of $3.30.Amount of Analyst CoverageGeron has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.33% of the outstanding shares of Geron have been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Geron has recently increased by 13.45%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Previous Next 1.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGeron has received a -26.38% net impact score from Upright. The largest negative impact of Geron in category "GHG emissions" is driven by its "Nonwoven fabric machines" and "Textile spinning machines" products. See details.Environmental SustainabilityThe Environmental Impact score for Geron is -3.23. Previous Next 3.0 News and Social Media Coverage News SentimentGeron has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Geron this week, compared to 4 articles on an average week.Search Interest69 people have searched for GERN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows31 people have added Geron to their MarketBeat watchlist in the last 30 days. This is an increase of 288% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Geron insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.10% of the stock of Geron is held by insiders.Percentage Held by Institutions73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Geron are expected to grow in the coming year, from ($0.34) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -10.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -10.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 7.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Geron Stock (NASDAQ:GERN)Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Read More GERN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GERN Stock News HeadlinesMarch 20, 2024 | marketbeat.comGeron Stock Doubles After Imetelstat Receives FDA Panel ApprovalGeron Inc. NASDAQ: GERN is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their lead drug is imetelstat, which blocks a protein called telomerase to treat specific blood cancers like myelofibrosis and myelodysplastic syndromes.March 20, 2024 | marketbeat.comGeron Stock Doubles After Imetelstat Receives FDA Panel Approval Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panelMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 27, 2024 | finance.yahoo.comGERN Mar 2024 3.500 putMarch 23, 2024 | americanbankingnews.comResearch Analysts Issue Forecasts for Geron Co.'s Q1 2024 Earnings (NASDAQ:GERN)March 22, 2024 | americanbankingnews.comWedbush Research Analysts Lower Earnings Estimates for Geron Co. (NASDAQ:GERN)March 19, 2024 | markets.businessinsider.comGeron Announces Pricing Of $150 Mln Underwritten Offering Of Common Stock, Pre-Funded WarrantsMarch 19, 2024 | msn.comGeron announces pricing of $150M underwritten offeringMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 19, 2024 | finance.yahoo.comGeron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsMarch 19, 2024 | americanbankingnews.comGeron's (GERN) "Outperform" Rating Reaffirmed at WedbushMarch 19, 2024 | americanbankingnews.comGeron (NASDAQ:GERN) Price Target Increased to $5.00 by Analysts at The Goldman Sachs GroupMarch 19, 2024 | americanbankingnews.comGeron (NASDAQ:GERN) Sees Unusually-High Trading Volume After Analyst UpgradeMarch 18, 2024 | finance.yahoo.comGERN240517C00003500 (GERN240517C00003500) Interactive Stock Chart - Yahoo FinanceMarch 18, 2024 | finance.yahoo.comGERN240517P00003500 (GERN240517P00003500) Interactive Stock Chart - Yahoo FinanceMarch 16, 2024 | finance.yahoo.comGERN Apr 2024 1.000 putMarch 16, 2024 | finance.yahoo.comGERN Apr 2024 1.500 callMarch 16, 2024 | wsj.comGeron Corp.March 15, 2024 | finance.yahoo.comMDGL Apr 2024 270.000 callMarch 15, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Geron (GERN)March 15, 2024 | msn.comGeron’s stock soars 95% after FDA advisory panel votes in favor of blood-disorder drugMarch 15, 2024 | investorplace.comWhy Is Geron (GERN) Stock Up 94% Today?March 15, 2024 | msn.comBiggest stock movers today: ADBE, GERN, and moreMarch 15, 2024 | seekingalpha.comGeron: Advisory Nod Boosts Approval Odds, But Market Position Remains HazyMarch 15, 2024 | msn.comGeron surges after FDA AdCom backing for lead drugMarch 15, 2024 | markets.businessinsider.comGeron Gets Favorable Votes From FDA Panel For Imetelstat In Treating Transfusion-Dependent AnemiaMarch 14, 2024 | bizjournals.comCancer drug from Peninsula company wins FDA advisory committee thumbs upSee More Headlines Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:GERN CUSIP37416310 CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees141Year FoundedN/APrice Target and Rating Average Stock Price Target$5.33 High Stock Price Target$6.00 Low Stock Price Target$5.00 Potential Upside/Downside+61.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,130,000.00 Net Margins-77,691.14% Pretax Margin-77,690.72% Return on Equity-63.33% Return on Assets-44.71% Debt Debt-to-Equity Ratio0.14 Current Ratio3.16 Quick Ratio3.16 Sales & Book Value Annual Sales$240,000.00 Price / Sales7,508.33 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book7.17Miscellaneous Outstanding Shares546,060,000Free Float529,131,000Market Cap$1.80 billion OptionableOptionable Beta0.55 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. John A. Scarlett M.D. (Age 73)Chairman of the Board, President & CEO Comp: $1.53MDr. Andrew J. Grethlein Ph.D. (Age 60)Executive VP & COO Comp: $847.2kMs. Michelle J. Robertson (Age 56)Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer Ms. Aron FeingoldVice President of Investor Relations & Corporate CommunicationsMr. Scott SamuelsExecutive VP, Chief Legal Officer & Corporate SecretaryMs. Shannon Odam (Age 49)Senior VP & Chief People Officer Ms. Melissa A. Kelly Behrs (Age 60)Executive VP of Business Operations & Chief Alliance Officer Comp: $753.22kMr. Anil Kapur (Age 53)Executive VP of Corporate Strategy & Chief Commercial Officer Comp: $654.89kMr. Edward E. Koval (Age 62)Executive VP & Chief Business Officer Dr. Faye Feller M.D. (Age 41)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsDynavax TechnologiesNASDAQ:DVAXMannKindNASDAQ:MNKDIronwood PharmaceuticalsNASDAQ:IRWDLigand PharmaceuticalsNASDAQ:LGNDInnovivaNASDAQ:INVAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 1,914,328 shares on 3/11/2024Ownership: 5.231%Wellington Management Group LLPSold 920,655 shares on 3/5/2024Ownership: 1.737%American International Group Inc.Bought 6,123 shares on 2/28/2024Ownership: 0.047%Lazari Capital Management Inc.Sold 13,500 shares on 2/27/2024Ownership: 0.021%Price T Rowe Associates Inc. MDBought 16,501 shares on 2/16/2024Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions GERN Stock Analysis - Frequently Asked Questions Should I buy or sell Geron stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GERN shares. View GERN analyst ratings or view top-rated stocks. What is Geron's stock price target for 2024? 3 Wall Street research analysts have issued 12 month price objectives for Geron's stock. Their GERN share price targets range from $5.00 to $6.00. On average, they predict the company's share price to reach $5.33 in the next year. This suggests a possible upside of 61.6% from the stock's current price. View analysts price targets for GERN or view top-rated stocks among Wall Street analysts. How have GERN shares performed in 2024? Geron's stock was trading at $2.11 at the start of the year. Since then, GERN stock has increased by 56.4% and is now trading at $3.30. View the best growth stocks for 2024 here. Are investors shorting Geron? Geron saw a increase in short interest in March. As of March 15th, there was short interest totaling 50,950,000 shares, an increase of 13.4% from the February 29th total of 44,910,000 shares. Based on an average daily trading volume, of 10,820,000 shares, the short-interest ratio is currently 4.7 days. View Geron's Short Interest. When is Geron's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GERN earnings forecast. How were Geron's earnings last quarter? Geron Co. (NASDAQ:GERN) released its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. Geron had a negative trailing twelve-month return on equity of 63.33% and a negative net margin of 77,691.14%. The business's revenue was down 77.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.10) EPS. What ETFs hold Geron's stock? ETFs with the largest weight of Geron (NASDAQ:GERN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), WisdomTree BioRevolution Fund (WDNA), Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What is John A. Scarlett's approval rating as Geron's CEO? 5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), Organigram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO). Who are Geron's major shareholders? Geron's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.26%), Vanguard Group Inc. (5.23%), Vivo Capital LLC (4.45%), Wellington Management Group LLP (1.74%), Northern Trust Corp (0.94%) and Charles Schwab Investment Management Inc. (0.71%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis. View institutional ownership trends. How do I buy shares of Geron? Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GERN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.